奥密克戎BA.4与BA.5亚系流行期COVID-19 mRNA疫苗有效性及不同接种状态下的疾病严重程度估计
该测试阴性病例对照研究纳入美国10个州2021年12月16日至2022年8月20日急诊/紧急护理就诊及住院的成人COVID-19样疾病患者,评估BA.4/BA.5流行期2、3、4剂mRNA疫苗的有效性(VE),并比较不同奥密克戎亚系流行期住院患者的疾病严重程度。结果:BA.4/BA.5期急诊/紧急护理就诊者中23.2% SARS-CoV-2阳性,住院者中17.1%阳性;对住院的VE在第二剂接种≥150天后为25%,第三剂后7-119天为68%,第三剂后≥120天为36%;≥65岁第四剂后7-59天VE为66%,≥60天为57%。住院COVID-19患者ICU入住或院内死亡在BA.1期为21.4%,BA.4/BA.5期为14.7%(标准化均数差0.17)。结论:随时间推移VE下降,加强针后VE高于仅基础免疫。
要点
- BA.4/BA.5流行期,第三剂mRNA疫苗对住院的VE在接种后7-119天为68%(95%CI 50%-80%),≥120天降至36%(95%CI 29%-42%)。
- 第二剂接种≥150天后对住院的VE仅为25%(95%CI 17%-32%)。
- ≥65岁人群第四剂后7-59天对住院的VE为66%(95%CI 53%-75%),≥60天为57%(95%CI 44%-66%)。
- 住院COVID-19患者ICU入住或院内死亡比例:BA.1期21.4% vs BA.4/BA.5期14.7%(标准化均数差0.17)。
- 随时间推移距末次接种越久VE越低,接受1或2剂加强针者VE高于仅基础免疫。
适用人群与场景
- 免疫功能正常的成人,具有COVID-19样疾病并接受SARS-CoV-2分子检测,数据来自美国10个州的急诊科、紧急护理就诊和住院(2021年12月16日至2022年8月20日)。
- 住院COVID-19患者用于比较不同奥密克戎亚系流行期的疾病严重程度。
研究设计与关键结果
- 研究类型:测试阴性病例对照研究,美国10个州,数据来自急诊/紧急护理就诊和住院(2021年12月16日至2022年8月20日),分析时间2022年8月2日至9月21日。
- BA.4/BA.5流行期共82 229例急诊/紧急护理就诊的COVID-19样疾病患者(中位年龄51岁,IQR 33-70;女性49 682例,60.4%),其中19 114例(23.2%)SARS-CoV-2检测阳性。
- 住院患者21 007例(中位年龄71岁,IQR 58-81;女性11 209例,53.4%),其中3 583例(17.1%)SARS-CoV-2检测阳性。
- 对住院的VE:第二剂接种≥150天后为25%(95%CI 17%-32%);第三剂接种后7-119天为68%(95%CI 50%-80%);第三剂接种后≥120天(中位235天,IQR 204-262)为36%(95%CI 29%-42%)。
- ≥65岁接受第四剂者:接种后7-59天VE为66%(95%CI 53%-75%),接种后≥60天(中位88天,IQR 75-105)VE为57%(95%CI 44%-66%)。
- 住院COVID-19患者中,ICU入住或院内死亡在BA.1期占21.4%,在BA.4/BA.5期占14.7%(标准化均数差0.17)。
证据类型、等级与局限
- 证据类型:测试阴性病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,随时间推移距末次接种越久,对就医性COVID-19的保护性VE越低;与仅基础免疫相比,接受1或2剂加强针后估计VE更高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Recent SARS-CoV-2 Omicron variant sublineages, including BA.4 and BA.5, may be associated with greater immune evasion and less protection against COVID-19 after vaccination.
OBJECTIVES: To evaluate the estimated vaccine effectiveness (VE) of 2, 3, or 4 doses of COVID-19 mRNA vaccination among immunocompetent adults during a period of BA.4 or BA.5 predominant circulation; and to evaluate the relative severity of COVID-19 in hospitalized patients across Omicron BA.1, BA.2 or BA.2.12.1, and BA.4 or BA.5 sublineage periods.
DESIGN, SETTING, AND PARTICIPANTS: This test-negative case-control study was conducted in 10 states with data from emergency department (ED) and urgent care (UC) encounters and hospitalizations from December 16, 2021, to August 20, 2022. Participants included adults with COVID-19-like illness and molecular testing for SARS-CoV-2. Data were analyzed from August 2 to September 21, 2022.
EXPOSURES: mRNA COVID-19 vaccination.
MAIN OUTCOMES AND MEASURES: The outcomes of interest were COVID-19 ED or UC encounters, hospitalizations, and admission to the intensive care unit (ICU) or in-hospital death. VE associated with protection against medically attended COVID-19 was estimated, stratified by care setting and vaccine doses (2, 3, or 4 doses vs 0 doses as the reference group). Among hospitalized patients with COVID-19, demographic and clinical characteristics and in-hospital outcomes were compared across sublineage periods.
RESULTS: During the BA.4 and BA.5 predominant period, there were 82 229 eligible ED and UC encounters among patients with COVID-19-like illness (median [IQR] age, 51 [33-70] years; 49 682 [60.4%] female patients), and 19 114 patients (23.2%) had test results positive for SARS-CoV-2; among 21 007 hospitalized patients (median [IQR] age, 71 [58-81] years; 11 209 [53.4%] female patients), 3583 (17.1 %) had test results positive for SARS-CoV-2. Estimated VE against hospitalization was 25% (95% CI, 17%-32%) for receipt of 2 vaccine doses at 150 days or more after receipt, 68% (95% CI, 50%-80%) for a third dose 7 to 119 days after receipt, and 36% (95% CI, 29%-42%) for a third dose 120 days or more (median [IQR], 235 [204-262] days) after receipt. Among patients aged 65 years or older who had received a fourth vaccine dose, VE was 66% (95% CI, 53%-75%) at 7 to 59 days after vaccination and 57% (95% CI, 44%-66%) at 60 days or more (median [IQR], 88 [75-105] days) after vaccination. Among hospitalized patients with COVID-19, ICU admission or in-hospital death occurred in 21.4% of patients during the BA.1 period vs 14.7% during the BA.4 and BA.5 period (standardized mean difference: 0.17).
CONCLUSIONS AND RELEVANCE: In this case-control study of COVID-19 vaccines and illness, VE associated with protection against medically attended COVID-19 illness was lower with increasing time since last dose; estimated VE was higher after receipt of 1 or 2 booster doses compared with a primary series alone.
参考来源
- Link-Gelles R, Levy ME, Natarajan K, et al. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023. PMID: 36920396. doi:10.1001/jamanetworkopen.2023.2598
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。